EPCAM and carcinoma: To this end, a novel bispecific antibody (CD73xEpCAM) was developed to bind both CD73 and EpCAM, a common exosome surface marker and has demonstrated potent inhibition of CD73+/EpCAM+ carcinoma cell lines in vitro [68].